35
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      An innovative approach to treating dental decay in children. A new anti-caries agent.

      Journal of Materials Science. Materials in Medicine
      Springer Nature America, Inc

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The aim of this work is to evaluate the antimicrobial and cytotoxic activity of a formulation containing silver nanoparticles and chitosan, provisionally called nano silver fluoride (NSF), against Streptococcus mutans in comparison to chlorhexidine and silver diamine fluoride (SDF). The product was characterised by transmission electron microscopy and UV-Vis absorption spectroscopy. The minimum inhibition concentration (MIC) was evaluated by the spectrophotometric microdilution method and turbidity. The minimum bactericide concentration (MBC) was evaluated in brain heart infusion plates, and cytotoxicity was evaluated by haemolytic activity. The MIC and MBC for NSF were, respectively, 33.54 ± 14.52 and 50.32 µg/mL; for SDF were 33.33 ± 14.43 and 50.0 µg/mL, respectively; and for CHX were 3.3 ± 0.5 and 6 µg/mL, respectively. An ANOVA for MIC gave P = 0.032, and for MBC P = 0.035. The cytotoxic effect of NSF compared to SDF demonstrated a statistically significant difference in the MIC value (t test P < 0.05). The NSF formulation may be effective against S. mutans with much lower doses, may have lower toxicity than SDF, and may not stain teeth.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: not found
          • Article: not found

          A review of chitin and chitosan applications

            • Record: found
            • Abstract: found
            • Article: not found

            A sensitive and quick microplate method to determine the minimal inhibitory concentration of plant extracts for bacteria.

            J N Eloff (1998)
            Agar diffusion techniques are used widely to assay plant extracts for antimicrobial activity, but there are problems associated with this technique. A micro-dilution technique was developed using 96-well microplates and tetrazolium salts to indicate bacterial growth. p-Iodonitrotetrazolium violet [0.2 mg/ml] gave better results than tetrazolium red or thiazolyl blue. The method is quick, worked well with Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa, and Escherichia coli and with non-aqueous extracts from many different plants. The method gave reproducible results; required only 10-25 microliters of extract to determine minimal inhibitory concentrations, distinguished between microcidal and microstatic effects, and provided a permanent record of the results. Using S. aureus, and a Combretum molle extract, the technique was 32 times more sensitive than agar diffusion techniques and was not sensitive to culture age of the test organism up to 24 hours. The S. aureus culture could be stored up to 10 days in a cold room with little effect on the assay results. This method was useful in screening plants for antimicrobial activity and for the bioassay-guided isolation of antimicrobial compounds from plants. MIC values determined for sulfisoxazole, norfloxacin, gentamicin, and nitrofuratoin were similar to values indicated in the literature but values obtained with trimethroprim and ampicillin were higher with some bacteria.
              • Record: found
              • Abstract: found
              • Article: not found

              The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.

              The efficient sequestration of hemoglobin by the red blood cell membrane and the presence of multiple hemoglobin clearance mechanisms suggest a critical need to prevent the buildup of this molecule in the plasma. A growing list of clinical manifestations attributed to hemoglobin release in a variety of acquired and iatrogenic hemolytic disorders suggests that hemolysis and hemoglobinemia should be considered as a novel mechanism of human disease. Pertinent scientific literature databases and references were searched through October 2004 using terms that encompassed various aspects of hemolysis, hemoglobin preparations, clinical symptoms associated with plasma hemoglobin, nitric oxide in hemolysis, anemia, pulmonary hypertension, paroxysmal nocturnal hemoglobinuria, and sickle-cell disease. Hemoglobin is released into the plasma from the erythrocyte during intravascular hemolysis in hereditary, acquired, and iatrogenic hemolytic conditions. When the capacity of protective hemoglobin-scavenging mechanisms has been saturated, levels of cell-free hemoglobin increase in the plasma, resulting in the consumption of nitric oxide and clinical sequelae. Nitric oxide plays a major role in vascular homeostasis and has been shown to be a critical regulator of basal and stress-mediated smooth muscle relaxation and vasomotor tone, endothelial adhesion molecule expression, and platelet activation and aggregation. Thus, clinical consequences of excessive cell-free plasma hemoglobin levels during intravascular hemolysis or the administration of hemoglobin preparations include dystonias involving the gastrointestinal, cardiovascular, pulmonary, and urogenital systems, as well as clotting disorders. Many of the clinical sequelae of intravascular hemolysis in a prototypic hemolytic disease, paroxysmal nocturnal hemoglobinuria, are readily explained by hemoglobin-mediated nitric oxide scavenging. A growing body of evidence supports the existence of a novel mechanism of human disease, namely, hemolysis-associated smooth muscle dystonia, vasculopathy, and endothelial dysfunction.

                Author and article information

                Journal
                10.1007/s10856-014-5221-5
                24818873

                Comments

                Comment on this article

                Related Documents Log